PloS one · 2026
A digestive cartridge reduces intestinal injury in a murine model of necrotizing enterocolitis.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Wang Sarah Z, Fernandes Djanira, Tsikis Savas T, Hirsch Thomas I, Pan Amy, Quigley Mikayla, Ruiz Valeria, Fligor Scott C, Petty Carter R, Loring Greta, Davia Stephen, Kang Juhye, Puder Mark
Аннотация
BACKGROUND: Formula feeding is associated with necrotizing enterocolitis (NEC), a life-threatening gastrointestinal illness affecting premature infants. The presence of undigested fat in enteral formula may mediate NEC severity. The immobilized lipase cartridge (ILC) is an FDA-cleared digestive device that hydrolyzes triglyceride fat in formula into readily absorbable free fatty acids and monoglycerides. We hypothesized that use of a new ILC prototype designed to support increased feeding frequency in infants will reduce NEC mortality and disease severity in a murine model.
METHODS: NEC was induced in C57BL/6J mice from post-natal day 4-6 via oral gavage of lipopolysaccharide-containing formula 4x/day and hypoxia (5% O2) exposure 2x/day. Littermates were randomized to one of five groups: dam-fed (normal controls), ILC-digested formula, placebo-processed formula, NEC + ILC-digested formula, NEC+placebo-processed formula. Weights and mortality were measured daily. Mice were euthanized on P7 for assessment of NEC severity.
RESULTS: Normal controls had better survival rates than formula-fed and NEC mice. The NEC + ILC group exhibited lower clinical and histologic severity scores compared to the NEC+placebo group on masked evaluation.
CONCLUSION: The administration of formula pre-digested by the ILC improved clinical sickness, gut appearance, and histologic severity of NEC compared to placebo. These findings support further investigation of the ILC as a non-invasive, preventive therapy for NEC in humans.
METHODS: NEC was induced in C57BL/6J mice from post-natal day 4-6 via oral gavage of lipopolysaccharide-containing formula 4x/day and hypoxia (5% O2) exposure 2x/day. Littermates were randomized to one of five groups: dam-fed (normal controls), ILC-digested formula, placebo-processed formula, NEC + ILC-digested formula, NEC+placebo-processed formula. Weights and mortality were measured daily. Mice were euthanized on P7 for assessment of NEC severity.
RESULTS: Normal controls had better survival rates than formula-fed and NEC mice. The NEC + ILC group exhibited lower clinical and histologic severity scores compared to the NEC+placebo group on masked evaluation.
CONCLUSION: The administration of formula pre-digested by the ILC improved clinical sickness, gut appearance, and histologic severity of NEC compared to placebo. These findings support further investigation of the ILC as a non-invasive, preventive therapy for NEC in humans.